Core Viewpoint - The company reported a revenue increase of approximately 3.7% year-on-year for the first half of 2025, driven by sales of coated stents and left atrial appendage occluders, despite a significant decline in net profit due to non-recurring items [1] Financial Performance - Revenue for the first half of 2025 was approximately 677 million, an increase of about 3.7% year-on-year [1] - Gross profit was approximately 498 million, representing a year-on-year decrease of about 3.4% [1] - Profit attributable to shareholders was 55.074 million, a significant decrease of 73.21% year-on-year [1] - Earnings per share were 1.3 cents [1] Margin Analysis - Gross margin decreased by 5.3 percentage points year-on-year to approximately 73.6% [1] - The decline in gross margin was attributed to the impact of centralized procurement policies, which led to a decrease in sales prices for certain products in specific regions, as well as changes in the sales mix [1]

Core Points - The company, Xianjian Technology (01302), reported a mid-year revenue of approximately 677 million, representing a year-on-year increase of about 3.7% [1] - Gross profit was approximately 498 million, showing a year-on-year decrease of about 3.4% [1] - Profit attributable to shareholders was 55.074 million, a significant year-on-year decrease of 73.21%, with earnings per share at 1.3 cents [1] Revenue and Profit Analysis - The increase in revenue was primarily driven by higher sales of coated stents and left atrial appendage occluders [1] - The gross profit margin decreased by 5.3 percentage points year-on-year to approximately 73.6%, mainly due to the impact of centralized procurement policies leading to a decline in sales prices of certain products in specific regions, as well as changes in the sales mix [1] - The decrease in net profit was mainly attributed to fluctuations in non-recurring items [1]